Thomas Dyrberg

Directeur/Membre du Conseil chez Lux Biosciences, Inc.

Profil

Thomas Dyrberg is currently a Director at Lux Biosciences, Inc., Kanyos Bio, Inc., Nuvelution Pharma, Inc., and Theia, Inc. He is also a Senior Advisor at Novo Holdings AS (Denmark) and a Managing Partner at Novo Ventures 1 A. Previously, he served as the Chief Executive Officer at Novo Nordisk Fonden and the Deputy Chairman at Veloxis Pharmaceuticals A. He has also held positions as Chairman at Hemofocus ApS, Director at Sapphire Therapeutics, Inc., Director at Gloucester Pharmaceuticals, Inc., Director at BioMimetic Therapeutics, Inc., Independent Director at Galera Therapeutics, Inc., Independent Director at IVERIC bio, Inc., Director at AlloCure, Inc., Director at Cell Medica Switzerland AG, Director at PanOptica, Inc., Director at Imagen Biotech, Inc., and Independent Director at Entasis Therapeutics, Inc. Additionally, he worked as a Manager-International Clinical Project at Novo Nordisk A and as a Principal at The Scripps Research Institute.
Dr. Dyrberg holds a doctorate degree from the University of Copenhagen, conferred in 1986 and 1981.

Postes actifs de Thomas Dyrberg

Sociétés	Poste	Début
Lux Biosciences, Inc.	Directeur/Membre du Conseil	-
Theia, Inc.	Directeur/Membre du Conseil	-
Novo Holdings A/S (Denmark)	Corporate Officer/Principal	-
Kanyos Bio, Inc.	Directeur/Membre du Conseil	-

Anciens postes connus de Thomas Dyrberg

Sociétés	Poste	Fin
Novo Ventures 1 A/S	Private Equity Investor	01/12/2025
PRAXIS PRECISION MEDICINES, INC.	Directeur/Membre du Conseil	01/10/2020
GALERA T COM USD0.	Directeur/Membre du Conseil	06/11/2019
IVERIC BIO, INC.	Directeur/Membre du Conseil	15/05/2019
VELOXIS PHARMACEUTICALS A/S	Directeur/Membre du Conseil	28/07/2016